RxDoctor Payments Data

Barbara Kennedy-Funtila, MD

Internal Medicine · Modesto, CANPI 1700874260

Payments from drug & device makers

$368in general payments, 2019–2025

Across 15 payments — averaging $24.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$102
  • Boehringer Ingelheim$45
  • Pfizer$32
  • Novartis$31
  • Novo Nordisk$27
  • Exact Sciences$25
  • plus $106 from 5 others

What the payments were for

  • Food & beverage$368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$368 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$225,767
Medicare patients
534
Services billed
2,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$79,422
EliquisApixaban95$75,761
JardianceEmpagliflozin48$51,439
JanuviaSitagliptin Phosphate40$46,594
XareltoRivaroxaban29$33,664
Breo ElliptaFluticasone/Vilanterol46$20,005
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$14,525
Atorvastatin Calcium1,020$14,393
FarxigaDapagliflozin Propanediol14$13,870
MounjaroTirzepatide14$13,355
MyrbetriqMirabegron15$12,556
Levothyroxine Sodium793$11,707
TrulicityDulaglutide11$9,667
Losartan Potassium658$8,029
Spiriva RespimatTiotropium Bromide15$7,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$27$79,42274 claims
PfizerEliquis$32$75,76195 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$45$66,20479 claims
MerckJanuvia$19$46,59440 claims
GSKBreo Ellipta, Trelegy Ellipta$23$34,53070 claims
Lilly USA, LLCMounjaro, Trulicity$17$23,02225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →